Simple and rapid synchronous fluorometric methods were adopted and validated for the simultaneous analysis of a binary mixture of diphenhydramine (DIP) and ibuprofen (IBU) (Mix I) or DIP and phenylephrine (PHE) (Mix II) in their co-formulated pharmaceuticals without prior separation. Analysis of Mix I is based on the measurement of the peak amplitudes (D1 ) of synchronous fluorescence intensities at 265.1 nm for DIP and 260 nm for IBU. The relationship between the concentration and the amplitude of the first-derivative synchronous fluorescence spectra showed good linearity over the concentration ranges 0.50-10.00 μg ml-1 and 0.50-7.90 μg ml-1 for DIP and IBU, respectively. Analysis of Mix II was based on measurement of the peak amplitude (D1 ) synchronous fluorescence intensities at 230 nm for DIP and at 253.9 nm for PHE. Moreover, for Mix II, the peak amplitude (D2 ) synchronous fluorescence intensities were measured at 227.9 nm for DIP and at 264.9 nm for PHE. Calibration plots were rectilinear over the concentration range 0.30-3.50 μg ml-1 and 0.03-0.75 μg ml-1 for DIP and PHE, respectively. The proposed methods were successfully applied to determine the studied compounds in pure form and in pharmaceutical preparations.

中文翻译：

---

同步分光光度法同时测定组合药物制剂中的苯海拉明和布洛芬或去氧肾上腺素。

采用了简单快速的同步荧光法，并验证了他们共同配制的药物中苯海拉明（DIP）和布洛芬（IBU）（Mix I）或DIP和去氧肾上腺素（PHE）（Mix II）的二元混合物的同时分析结果，而没有事先分离。混合物I的分析基于DIP和IBU的同步荧光强度在265.1 nm和260 nm的峰值幅度（D1）的测量。一阶同步荧光光谱的浓度与幅度之间的关系在DIP和IBU的浓度范围分别为0.50-10.00μgml-1和0.50-7.90μgml-1时表现出良好的线性。混合物II的分析基于DIP在230 nm处和PHE在253.9 nm处的峰值振幅（D1）同步荧光强度的测量。此外，对于Mix II，在DIP的227.9 nm和PHE的264.9 nm处测量了峰值振幅（D2）同步荧光强度。DIP和PHE的浓度范围分别在0.30-3.50μgml-1和0.03-0.75μgml-1的范围内是线性的。所提出的方法已成功地用于确定所研究化合物的纯形式和药物制剂。